Stereotactic Ablative Radiotherapy May Improve Outcomes in Some Patients With Oligometastatic Tumors
In patients with a controlled primary tumor and up to 5 oligometastatic lesions, delivering stereotactic ablative radiotherapy was associated...
Should Oncologists Recommend Cannabis?
A recent survey of 400 clinical oncologists found that 80% discuss the use of medical cannabis with their patients, and although nearly 50% recommend it...
Hippocampus-Sparing Whole-Brain Radiotherapy and Neurocognitive Function in Patients With Brain Metastases
Analysis of a phase III trial has confirmed that conformal avoidance of the hippocampal dentate gyrus using intensity-modulated radiotherapy...
Using Tumor‑Infiltrating Lymphocytes to Treat Metastatic Melanoma
Steven A. Rosenberg, MD, PhD, Chief of Surgery at the National Cancer Institute (NCI), began his pioneering research in adoptive cell transfer using interleukin...
Progress Made in Identifying Gene-Signature Biomarkers in Renal Cell Carcinoma
A new analysis of the phase III IMmotion151 trial identified gene signatures in renal cell carcinoma that correlate with improved progression-free survival...
Donald Abrams: Should Oncologists Recommend Cannabis?
William Sharfman: Encorafenib and Binimetinib in Metastatic Melanoma
Amitabh Gulati: Challenges Presented by the Parenteral Opioid Shortage
Timothy Triche: Genomic Profiling in Younger Patients With Cancer
Christopher Wild: Global Burden of Cancer on the Rise
More Top Stories
Encorafenib and Binimetinib: A New Benchmark in Metastatic Melanoma Therapy?
IN JULY 2018, the U.S. Food and Drug Administration (FDA) approved the combination of the oral BRAF inhibitor encorafenib (Braftovi) and the oral MEK inhibitor binimetinib (Mektovi) for BRAF V600E– or V600K– positive metastatic melanoma. The FDA approval was based on the results of the COLUMBUS...
ECHELON-2: Brentuximab Vedotin Plus Chemotherapy in CD30-Positive Peripheral T-Cell Lymphoma
As reported by Horwitz et al in The Lancet, the phase III ECHELON-2 trial showed that brentuximab vedotin (Adcetris) plus cyclophosphamide, doxorubicin, and prednisone (CHP) improved progression-free and overall survival vs cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in...
The Skin Cancer Foundation Raises $600,000 at Gala
The Skin Cancer Foundation recently held its 22nd annual Gala at The Plaza Hotel in New York. The Champions for Change Gala is the Foundation’s signature fundraising event, and $600,000 was raised to support the organization’s educational campaigns, community programs, and research initiatives....
Artificial Intelligence–Based Smartphone App Decreases Pain and Reduces Inpatient Hospitalizations in Patients With Cancer
A smartphone application utilizing elements of artificial intelligence was associated with improved cancer pain outcomes and a significant reduction in pain-related hospital admissions, according to data presented at the 2018 Palliative and Supportive Care in Oncology Symposium.1 Results of the...
RSNA 2018: Mammography Screening Beyond Age 75
Women aged 75 years and older may benefit from continued screening mammograms because of the comparatively high incidence of breast cancer found in this age group, according to a study presented at the Annual Meeting of the Radiological Society of North America (RSNA) (Abstract SSA01-04)....
Role of Genomic Profiling in Younger Patients With Cancer
Although overall cancer survival rates continue to improve among all age groups in the United States—there are currently an estimated 15.5 million cancer survivors, and that number is expected to increase to 20.3 million by 20261—survival rates for adolescents and young adults with cancer (AYAs)...
RSNA 2018: Breast Cancer Risk-Based Mammography Screening in Younger Women
A new, large-scale study of more than 5 million mammograms found that annual mammography screening beginning at age 30 may benefit women with at least 1 of 3 specific risk factors: dense breasts, a personal history of breast cancer, or a family history of breast cancer. The study was presented at...
Julie Vose, MD, MBA, and Loretta J. Nastoupil, MD, on Large B-Cell Lymphoma: Real-World Experience With CAR T-Cell Therapy
Steven M. Horwitz, MD, on PTCL and CTCL: Trial Results on Cerdulatinib
Andrew D. Seidman, MD, and Miguel Martín, MD, PhD, on Triple-Negative Breast Cancer: Results From the CIBOMA/GEICAM Trial
Kathryn J. Ruddy, MD, MPH, on Breast Cancer and Quality of Life: Expert Perspective
